Invex operates in the biopharmaceutical industry, seeking to develop efficacious treatments for neurological conditions resulting from raised intracranial pressure (ICP). ICP is a serious issue in a range of neurological conditions, including idiopathic intracranial hypertension, traumatic brain injury or acute stroke.

Invex is focused on research and development centred around understanding and defining the mechanisms that regulate pressure in the brain, and in particular the potential to repurpose an already approved drug, Exenatide, to reduce intracranial pressure and address a significant unmet medical need. Invex has trade marked its repurposed Exenatide as Presendin™.